Bristol-Myers Squibb EBIT

The latest EBIT for BMY is $14B as of September 2026. That compares with $7.2B in the prior-year period — up 88.2% year over year. That is below the Healthcare sector average of $2T. Investors often review this figure alongside Bristol-Myers Squibb's historical trend and sector peers before judging valuation or financial health.

Over the past year, BMY's EBIT moved from $7.2B to $14B — a 88.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb's operating scale or balance-sheet position.

Against Healthcare companies, BMY currently prints $14B for EBIT, while the sector average sits near $2T. That is roughly 99.3% below the sector mean. Large gaps often invite a closer look at Bristol-Myers Squibb's growth, margins, and balance sheet.

A EBIT figure of $14B for BMY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $2T. Explore the charts below for those layers of context.

After noting BMY's EBIT ($14B), review year-over-year change from $7.2B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.